Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Exercises Right To Buy Out Novartis Consumer Healthcare JV For $13bn

Executive Summary

GSK will buy Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture, established in 2014, for $13bn (£9.2bn). It expects power brands to deliver operating margins approaching mid-20s by 2022. GSK will also initiate a strategic review of Horlicks and other consumer nutrition products to support transaction funding.

 

 

Advertisement

Related Content

Why The M&A Boom Many Expected In 2018 Didn’t Happen
Why The M&A Boom Many Expected In 2018 Didn’t Happen
Biopharma Quarterly Dealmaking Statistics, Q1 2018
GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
Deal Watch: Opportunity Knocks For Partnerships In Asia
What Will Novartis Do With $13bn Cash Pile From GSK?
GSK Drops Out Of Auction For Pfizer's Consumer Health Unit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100640

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel